RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2026

Feb 20, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2026-02-17

Reporting Person: Smith Hunter C (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-17	Common Stock	S	1200	$99.415	Disposed	117266	Direct
2026-02-17	Common Stock	S	200	$100.52	Disposed	117066	Direct
2026-02-17	Common Stock	S	900	$101.70	Disposed	116166	Direct
2026-02-17	Common Stock	S	1069	$103.0024	Disposed	115097	Direct
2026-02-17	Common Stock	S	200	$103.84	Disposed	114897	Direct
2026-02-19	Common Stock	S	1308	$100.2698	Disposed	113589	Direct
2026-02-19	Common Stock	S	1692	$100.9189	Disposed	111897	Direct
2026-02-19	Common Stock	S	800	$102.0951	Disposed	111097	Direct
2026-02-19	Common Stock	S	585	$103.2828	Disposed	110512	Direct

Footnotes

F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.

F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.